Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Drivers of costs associated with reperfusion therapy in acute stroke: the Interventional Management of Stroke III Trial.

Simpson KN, Simpson AN, Mauldin PD, Hill MD, Yeatts SD, Spilker JA, Foster LD, Khatri P, Martin R, Jauch EC, Kleindorfer D, Palesch YY, Broderick JP; IMS III Investigators.

Stroke. 2014 Jun;45(6):1791-8. doi: 10.1161/STROKEAHA.113.003874. Epub 2014 May 13.

PMID:
24876261
[PubMed - indexed for MEDLINE]
2.

Alberta Stroke Program early computed tomography score to select patients for endovascular treatment: Interventional Management of Stroke (IMS)-III Trial.

Hill MD, Demchuk AM, Goyal M, Jovin TG, Foster LD, Tomsick TA, von Kummer R, Yeatts SD, Palesch YY, Broderick JP; IMS3 Investigators.

Stroke. 2014 Feb;45(2):444-9. doi: 10.1161/STROKEAHA.113.003580. Epub 2013 Dec 12.

PMID:
24335227
[PubMed - indexed for MEDLINE]
3.

Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke: experience from Australian stroke center.

Tan Tanny SP, Busija L, Liew D, Teo S, Davis SM, Yan B.

Stroke. 2013 Aug;44(8):2269-74. doi: 10.1161/STROKEAHA.113.001295. Epub 2013 Jun 18.

PMID:
23780955
[PubMed - indexed for MEDLINE]
Free Article
4.

Collaterals at angiography and outcomes in the Interventional Management of Stroke (IMS) III trial.

Liebeskind DS, Tomsick TA, Foster LD, Yeatts SD, Carrozzella J, Demchuk AM, Jovin TG, Khatri P, von Kummer R, Sugg RM, Zaidat OO, Hussain SI, Goyal M, Menon BK, Al Ali F, Yan B, Palesch YY, Broderick JP; IMS III Investigators.

Stroke. 2014 Mar;45(3):759-64. doi: 10.1161/STROKEAHA.113.004072. Epub 2014 Jan 28.

PMID:
24473178
[PubMed - indexed for MEDLINE]
5.

Evaluation of interval times from onset to reperfusion in patients undergoing endovascular therapy in the Interventional Management of Stroke III trial.

Goyal M, Almekhlafi MA, Fan L, Menon BK, Demchuk AM, Yeatts SD, Hill MD, Tomsick T, Khatri P, Zaidat OO, Jauch EC, Eesa M, Jovin TG, Broderick JP.

Circulation. 2014 Jul 15;130(3):265-72. doi: 10.1161/CIRCULATIONAHA.113.007826. Epub 2014 May 9.

PMID:
24815501
[PubMed - indexed for MEDLINE]
6.

Cost-effectiveness of tissue-type plasminogen activator in the 3- to 4.5-hour time window for acute ischemic stroke.

Tung CE, Win SS, Lansberg MG.

Stroke. 2011 Aug;42(8):2257-62. doi: 10.1161/STROKEAHA.111.615682. Epub 2011 Jun 30.

PMID:
21719767
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States.

Demaerschalk BM, Yip TR.

Stroke. 2005 Nov;36(11):2500-3. Epub 2005 Oct 13.

PMID:
16224087
[PubMed - indexed for MEDLINE]
Free Article
8.

A cost-utility analysis of mechanical thrombectomy as an adjunct to intravenous tissue-type plasminogen activator for acute large-vessel ischemic stroke.

Kim AS, Nguyen-Huynh M, Johnston SC.

Stroke. 2011 Jul;42(7):2013-8. doi: 10.1161/STROKEAHA.110.606889. Epub 2011 Jun 2.

PMID:
21636817
[PubMed - indexed for MEDLINE]
Free Article
9.

Hospitalization costs for acute ischemic stroke patients treated with intravenous thrombolysis in the United States are substantially higher than medicare payments.

Brinjikji W, Rabinstein AA, Cloft HJ.

Stroke. 2012 Apr;43(4):1131-3. doi: 10.1161/STROKEAHA.111.636142. Epub 2011 Dec 22.

PMID:
22198978
[PubMed - indexed for MEDLINE]
Free Article
10.

Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.

Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology.

Stroke. 2003 Aug;34(8):e109-37. Epub 2003 Jul 17. Erratum in: Stroke. 2003 Nov;34(11):2774.

PMID:
12869717
[PubMed - indexed for MEDLINE]
Free Article
11.

Challenges of decision making regarding futility in a randomized trial: the Interventional Management of Stroke III experience.

Yeatts SD, Martin RH, Coffey CS, Lyden PD, Foster LD, Woolson RF, Broderick JP, Di Tullio MR, Jungreis CA, Palesch YY; IMS III Investigators.

Stroke. 2014 May;45(5):1408-14. doi: 10.1161/STROKEAHA.113.003925. Epub 2014 Apr 3.

PMID:
24699059
[PubMed - indexed for MEDLINE]
12.

CLOTBUST-Hands Free: pilot safety study of a novel operator-independent ultrasound device in patients with acute ischemic stroke.

Barreto AD, Alexandrov AV, Shen L, Sisson A, Bursaw AW, Sahota P, Peng H, Ardjomand-Hessabi M, Pandurengan R, Rahbar MH, Barlinn K, Indupuru H, Gonzales NR, Savitz SI, Grotta JC.

Stroke. 2013 Dec;44(12):3376-81. doi: 10.1161/STROKEAHA.113.002713. Epub 2013 Oct 24. Erratum in: Stroke. 2014 Jan;45(1):e11.

PMID:
24159060
[PubMed - indexed for MEDLINE]
13.

Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study.

Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA.

JAMA. 2000 Mar 1;283(9):1145-50.

PMID:
10703776
[PubMed - indexed for MEDLINE]
14.

The totaled health risks in vascular events (THRIVE) score predicts ischemic stroke outcomes independent of thrombolytic therapy in the NINDS tPA trial.

Kamel H, Patel N, Rao VA, Cullen SP, Faigeles BS, Smith WS, Flint AC.

J Stroke Cerebrovasc Dis. 2013 Oct;22(7):1111-6. doi: 10.1016/j.jstrokecerebrovasdis.2012.08.017. Epub 2012 Nov 2.

PMID:
23122722
[PubMed - indexed for MEDLINE]
15.

Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs.

Tsui W, Pierre K, Massel D.

Can J Cardiol. 2005 Apr;21(5):423-31.

PMID:
15861260
[PubMed - indexed for MEDLINE]
17.

Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs.

Sandercock P, Berge E, Dennis M, Forbes J, Hand P, Kwan J, Lewis S, Lindley R, Neilson A, Wardlaw J.

Stroke. 2004 Jun;35(6):1490-7. Epub 2004 Apr 22.

PMID:
15105519
[PubMed - indexed for MEDLINE]
Free Article
18.

Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction.

Kaul P, Armstrong PW, Cowper PA, Eisenstein EL, Granger CB, Van de Werf F, Mark DB.

Am Heart J. 2005 Apr;149(4):637-44.

PMID:
15990746
[PubMed - indexed for MEDLINE]
19.

Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group.

Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, Levine SR, Broderick JP, Kwiatkowski TG, Frankel M, Brott TG, Walker MD.

Neurology. 1998 Apr;50(4):883-90.

PMID:
9566367
[PubMed - indexed for MEDLINE]
20.

A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction.

Kalish SC, Gurwitz JH, Krumholz HM, Avorn J.

J Gen Intern Med. 1995 Jun;10(6):321-30.

PMID:
7562123
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk